Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome

Authors:

Abstract
No abstract available
Funding Information
  • Novartis Pharmaceuticals UK Limited
  • Novartis Pharma AG
  • Novartis (GPP 2022)

This publication has 41 references indexed in Scilit: